04:46 PM EDT, 06/02/2025 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) reported late Monday positive results from a phase 3 study of Zepzelca plus atezolizumab as a first-line treatment for people with extensive-stage small cell lung cancer, following an induction therapy.

The study met both primary endpoints, showing statistically significant improvements in progression-free survival and overall survival compared with atezolizumab alone, the company said.

The maintenance therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months against 10.6 months for atezolizumab alone from the point of randomization, Jazz said.

The results were presented at the ASCO annual meeting and published in The Lancet, it said.